**Acknowledgements**

The authors acknowledge FEDER—Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020—Operational Program for Competitiveness and Internationalization (POCI), Portugal 2020, NORTE-01-0145-FEDER-000012, and PyloriBinders—*Helicobacter pylori*-specific biomaterials for antibiotic-free treatment/diagnostic of gastric infection (PTDC/ CTM-BIO/4043/2014).

[6] Piazuelo MB, Epplein M, Correa P. Gastric cancer: An infectious disease. Infectious

Nonantibiotic-Based Therapeutics Targeting *Helicobacter pylori*: From Nature to the Lab

http://dx.doi.org/10.5772/intechopen.81248

[7] Patel A, Shah N, Prajapati JB. Clinical appliance of probiotics in the treatment of *Helicobacter pylori* infection—A brief review. Journal of Microbiology, Immunology, and

[8] Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of *Helicobacter pylori* infection—The Maastricht V/Florence consensus

[9] Dang BN, Graham DY. *Helicobacter pylori* infection and antibiotic resistance: A WHO high priority? Nature Reviews. Gastroenterology & Hepatology. 2017;**14**(7):383-384 [10] Ricci V, Zarrilli R, Romano M. Voyage of *Helicobacter pylori* in human stomach: Odyssey

[11] Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: Relevance to the treatment of *Helicobacter pylori* infection. The Journal of Antimicrobial Chemotherapy. 1997;**39**:5-12 [12] Sherwood PV, Wibawa JID, Atherton JC, Jordan N, Jenkins D, Barrett DA, et al. Impact of acid secretion, gastritis, and mucus thickness on gastric transfer of antibiotics in rats.

[13] Vakil N. *Helicobacter pylori* treatment: A practical approach. The American Journal of

[14] Campo SMA, Zullo A, Hassan C, Morini S.Antibiotic treatment strategies for *Helicobacter pylori* infection. Recent Patents on Anti-Infective Drug Discovery. 2007;**2**(1):11-17 [15] Suzuki T, Matsuo K, Ito H, Sawaki A, Hirose K, Wakai K, et al. Smoking increases the treatment failure for *Helicobacter pylori* eradication. The American Journal of Medicine.

[16] Gonçalves IC, Henriques PC, Seabra CL, Martins MCL. The potential utility of chitosan micro/nanoparticles in the treatment of gastric infection. Expert Review of Anti-Infective

[17] Fernandes M, Gonçalves IC, Nardecchia S, Amaral IF, Barbosa MA, Martins MCL. Modulation of stability and mucoadhesive properties of chitosan microspheres for therapeutic gastric application. International Journal of Pharmaceutics. 2013;**454**(1):116-124 [18] Sogias I, Williams AC, Khutoryanskiy VV. Why is chitosan mucoadhesive? Biomacro-

[19] Deacon MP, McGurk S, Roberts CJ, Williams PM, Tendler SJ, Davies MC, et al. Atomic force microscopy of gastric mucin and chitosan mucoadhesive systems. The Biochemical

[20] Nogueira F, Gonçalves IC, Martins MCL. Effect of gastric environment on *Helicobacter pylori* adhesion to a mucoadhesive polymer. Acta Biomaterialia. 2012;**9**(2):5208-5215

Disease Clinics of North America. 2010;**24**(4):853-869

of a bacterium. Digestive and Liver Disease. 2002;**34**:2-8

Infection. 2014;**47**(5):429-437

report. Gut. 2017;**66**(1):6-30

Gut. 2002;**51**(4):490-495

2006;**119**:217-224

Therapy. 2014;**12**(8):981-992

molecules. 2008;**9**:1837-1842

Journal. 2000;**348**(3):557-563

Gastroenterology. 2006;**101**(3):497-499
